PFE heads into its July 28 earnings with shorts continuing to unwind, the Street growing more defensive, and the stock stuck near multi-year lows — a combination that makes the next few weeks more about fundamental credibility than positioning pressure.
The short-covering trend flagged in last week's note has continued. Short interest has dropped a further 10% over the past seven days to 2.7% of the free float — roughly 154 million shares — extending the retreat from the peak of around 200 million shares in late June. The ORTEX short score has eased in parallel, falling from 36.7 at the start of the week to 35.5 now, its lowest level in the window we have. This is consistent covering, not noise. Borrow conditions reinforce the picture: availability is exceptionally loose at 4,657% — meaning the lending pool holds nearly 47 shares available for every one currently borrowed — and the cost to borrow has dipped to 0.47%, down from 0.56% a week ago. Options traders are equally relaxed. The put/call ratio at 0.84 is running slightly below its 20-day average of 0.86, roughly one standard deviation below normal, suggesting no particular demand for downside protection ahead of earnings. The lending market and the options market are both telling the same story: this is not a stock that bears are currently rushing into.
The Street, however, is clearly becoming more guarded. Two actions in the past 48 hours stand out. JP Morgan's Chris Schott cut his price target from $30 to $28 on July 8 while keeping a Neutral rating — a move that narrows the implied upside from the current $24.07 price and signals reduced conviction in a near-term re-rating. HSBC went further on July 6, downgrading outright from Buy to Hold and trimming its target from $32 to $28. Both firms are converging on the same $28 level, which now also matches the analyst consensus mean of $28.93. The consensus implies roughly 20% upside from here, but the direction of travel among active movers is clearly lower. Factor scores add nuance: the 12-month forward EPS growth rank is at the 96th percentile — analysts see material earnings recovery ahead — while the dividend score sits at the 80th percentile, reflecting Pfizer's yield at current prices. EPS momentum over the past 30 and 90 days is weaker, ranking in the 31st and 42nd percentiles respectively, suggesting near-term estimate revisions are still running against the stock.
The bulls' case rests on the $60 billion revenue base, international exposure accounting for 40% of sales, and the earnings recovery embedded in forward estimates. Bears point to gross-to-net adjustments on premium products like Vyndaqel and Ibrance that are expected to weigh on revenue recognition, and the ongoing drag from COVID franchise normalisation. At 8.3x trailing earnings and 7.7x EV/EBITDA — both drifting lower over the past 30 days — valuation looks undemanding, but that has been true for most of the past year without attracting sustained buying. Close peers JNJ and BMY both gained more than 3% and 2% on the day respectively, while PFE managed only 1.5% — a pattern that has recurred through 2026.
Institutional ownership remains anchored by index-weight holders: BlackRock added roughly 24 million shares as of June 30 and holds 8.7% of the company, while State Street added a further 2.9 million. These are passive-flow driven additions rather than active conviction buys. Insider activity has been negligible — the only reportable trade in the 90-day window is a $51,400 sale by the Chief Accounting Officer in early June, a size that carries no meaningful signal. The stock is not being quietly bought by people who know it well.
The July 28 earnings print is now the defining event. With shorts pared back and options traders unbothered, any reset to consensus estimates or revenue guidance on gross-to-net pressures will have to be absorbed by long holders rather than squeezed bears — which is precisely what makes that print more consequential than it might otherwise appear.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
